ストックスクリーナーアプリを入手
29.18
1.01%
0.535
前日終値:
$28.64
開ける：
$29.14
24時間の取引高:
170.50K
Relative Volume:
0.08
時価総額：
$3.01B
収益：
$139.74M
当期純損益:
$-79.99M
株価収益率:
-28.72
EPS:
-1.0157
ネットキャッシュフロー:
$-360.05M
1週間 パフォーマンス:
+9.87%
1か月 パフォーマンス:
+6.71%
6か月 パフォーマンス:
+15.58%
1年 パフォーマンス:
+71.90%
1日の値動き範囲:
$28.81
$29.39
1週間の範囲:
$26.04
$29.39
52週間の値動き範囲:
$15.35
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
29.23 | 2.95B | 139.74M | -79.99M | -360.05M | -1.0157 |
VRTX
Vertex Pharmaceuticals Inc
|
435.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.86 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.89 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.09 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily
BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International ConferenceSlideshow - Seeking Alpha
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Yahoo Finance
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey
BEAM Technical Analysis | Trend, Signals & Chart Patterns | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance
ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus
Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus
Verve Therapeutics : VERV - 24/7 Wall St.
Beam Therapeutics presents AATD gene therapy trial data at ATS - Investing.com UK
Beam Therapeutics presents AATD gene therapy trial data at ATS By Investing.com - Investing.com Australia
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path - Stock Titan
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? - Yahoo Finance
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
HC Wainwright Expects Lower Earnings for Beam Therapeutics - MarketBeat
BEAM News Today | Why did Beam Therapeutics stock go up today? - MarketBeat
BEAM's Q1 loss wider than expected, revenues beat estimates - MSN
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 8%Should You Sell? - MarketBeat
Beam Therapeutics Stock Stumbles After Post-Rally Shakeout - TipRanks
BEAM Maintained by Bernstein -- Price Target Lowered to $39.00 - GuruFocus
AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts - Intellectia AI
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 – Company Announcement - Financial Times
Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story - Seeking Alpha
Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - Barchart.com
Beam Therapeutics to present sickle cell therapy data at EHA - Investing.com India
Beam Therapeutics to present sickle cell therapy data at EHA By Investing.com - Investing.com South Africa
Beam Therapeutics to Present Positive Biomarker Data from BEACON Trial of Ristoglogene Autogetemcel for Sickle Cell Disease at EHA2026 - Quiver Quantitative
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
Beam Therapeutics Inc (BEAM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Apr 01 '26 |
Sale |
24.58 |
30,078 |
739,317 |
1,047,205 |
| Simon Amy | Chief Medical Officer |
Apr 01 '26 |
Sale |
24.58 |
6,700 |
164,686 |
102,735 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Apr 01 '26 |
Sale |
24.58 |
3,242 |
79,688 |
51,171 |
| Bellon Christine | Chief Legal Officer |
Apr 01 '26 |
Sale |
24.58 |
5,956 |
146,398 |
109,711 |
| Ciaramella Giuseppe | President |
Apr 01 '26 |
Sale |
24.58 |
11,810 |
290,290 |
218,406 |
| Evans John M. | CEO |
Mar 30 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Mar 31 '26 |
Sale |
22.76 |
25,000 |
569,085 |
986,667 |
| Evans John M. | CEO |
Mar 30 '26 |
Sale |
22.37 |
25,000 |
559,230 |
986,667 |
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):